Literature DB >> 28350257

Intrahepatic mass-forming cholangiocarcinoma and solitary hypovascular liver metastases: is the differential diagnosis using diffusion-weighted MRI possible?

Jelena Djokić Kovač1, Danijel Galun2, Aleksandra Đurić-Stefanović1, Gordana Lilić1, Dragan Vasin1, Ljubica Lazić1, Dragan Mašulović1, Đorđije Šaranović1.   

Abstract

Background Intrahepatic mass-forming cholangiocellular carcinoma (IMC) is the second most common primary liver tumor. The differentiation between IMC and solitary hypovascular liver metastases (SHLM) represents a diagnostic challenge due to many overlapping magnetic resonance imaging (MRI) features. Purpose To determine the value of diffusion-weighted imaging (DWI) in addition to conventional MRI for the distinction between intrahepatic mass-forming cholangiocarcinoma and solitary hypovascular liver metastases. Material and Methods Fifty-three patients with pathologically proven IMC (n = 31) and SHLM (n = 22) who had undergone MRI and DWI before surgery or percutaneous biopsy were enrolled in this study. The following MRI features were analyzed: the size and shape of the lesion, presence of capsular retraction and segmental biliary dilatation, T2-weighted (T2W) signal intensity, the presence of target sign on DWI and enhancement pattern. Apparent diffusion coefficient (ADC) values were calculated for each lesion ( b = 800 s/mm2). Univariate and multivariate logistic regression analyses were used to identify significant differentiating features between IMCs and SHLMs. Results Univariate analysis revealed that following parameters favor diagnosis of IMCs over SHLMs: lobulating shape, heterogeneous T2W signal intensity, capsular retraction, segmental biliary dilatation, target sign on DWI and rim-like enhancement on arterial phase followed by progressive enhancement in delayed phases. ADC values measured in the periphery of the lesion were significantly lower in IMCs in comparison to SHLMs. Multivariate analysis revealed that target sign on DWI was the most significant predictor of IMCs. Conclusion Qualitative DWI analysis with target sign significantly improves diagnostic accuracy for differentiation among IMC and SHLM lesions.

Entities:  

Keywords:  Intrahepatic mass-forming cholangiocarcinoma; diffusion weighted imaging; magnetic resonance imaging (MRI); solitary hypovascular liver lesions

Mesh:

Year:  2017        PMID: 28350257     DOI: 10.1177/0284185117695666

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  4 in total

Review 1.  Imaging Spectrum of Intrahepatic Mass-Forming Cholangiocarcinoma and Its Mimickers: How to Differentiate Them Using MRI.

Authors:  Jelena Djokic Kovač; Aleksandra Janković; Aleksandra Đikić-Rom; Nikica Grubor; Andrija Antić; Vladimir Dugalić
Journal:  Curr Oncol       Date:  2022-01-30       Impact factor: 3.677

2.  Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma.

Authors:  Vincenza Granata; Roberta Fusco; Andrea Belli; Valentina Borzillo; Pierpaolo Palumbo; Federico Bruno; Roberta Grassi; Alessandro Ottaiano; Guglielmo Nasti; Vincenzo Pilone; Antonella Petrillo; Francesco Izzo
Journal:  Infect Agent Cancer       Date:  2022-03-28       Impact factor: 2.965

Review 3.  A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls.

Authors:  Federica De Muzio; Francesca Grassi; Federica Dell'Aversana; Roberta Fusco; Ginevra Danti; Federica Flammia; Giuditta Chiti; Tommaso Valeri; Andrea Agostini; Pierpaolo Palumbo; Federico Bruno; Carmen Cutolo; Roberta Grassi; Igino Simonetti; Andrea Giovagnoni; Vittorio Miele; Antonio Barile; Vincenza Granata
Journal:  Diagnostics (Basel)       Date:  2022-07-07

4.  Diagnostic performance of apparent diffusion coefficient values for the differentiation of intrahepatic cholangiocarcinoma from gastrointestinal adenocarcinoma liver metastases.

Authors:  Temel Fatih Yilmaz; Mehmet Ali Gultekin; Hacı Mehmet Turk; Mehmet Besiroglu; Dilek Hacer Cesme; Melih Simsek; Alpay Alkan; Huseyin Toprak
Journal:  Radiol Oncol       Date:  2021-12-22       Impact factor: 2.991

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.